University of Groningen

Chemoenzymatic approaches to obtain chiral-centered selenium compounds

Brondani, Patricia B.; Guilmoto, Nathalie M. A. F.; Dudek, Hanna M.; Fraaije, Marco W.; Andrade, Leandro H.

Published in:
Tetrahedron

DOI:
[10.1016/j.tet.2012.09.087](https://doi.org/10.1016/j.tet.2012.09.087)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Brondani, P. B., Guilmoto, N. M. A. F., Dudek, H. M., Fraaije, M. W., & Andrade, L. H. (2012). Chemoenzymatic approaches to obtain chiral-centered selenium compounds. *Tetrahedron*, 68(51), 10431-10436. <https://doi.org/10.1016/j.tet.2012.09.087>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chemoenzymatic approaches to obtain chiral-centered selenium compounds

Patrícia B. Brondani^a, Nathalie M.A.F. Guilmoto^a, Hanna M. Dudek^b, Marco W. Fraaije^b, Leandro H. Andrade^{a,*}

^a Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, SP 05508-900, São Paulo, Brazil

^b Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands

ARTICLE INFO

Article history:

Received 25 June 2012

Received in revised form 17 September 2012

Accepted 19 September 2012

Available online 26 September 2012

Keywords:

Selenium

Monooxygenase

Lipase

Selenium oxidation

ABSTRACT

The synthesis of chiral-centered selenium compounds is presented. Enantioselective oxidations of these organoselenium compounds were performed using a wide range of biocatalysts, including Baeyer–Villiger monooxygenases, oxidoreductases-containing *Aspergillus terreus* and lipase (Cal-B) in the presence of oxidants. Finally, efficient synthesis of enantiopure organoselenium compounds using a kinetic resolution approach mediated by Cal-B was achieved.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

Organoselenium compounds are very useful in organic synthesis, and they are regularly employed in the preparation of many organic compounds including natural products.¹ They can be used in nucleophilic, electrophilic, and radical reactions due to their chemical properties and can be incorporated into a variety of substrates under mild conditions.² Additionally, organoselenium compounds have shown biological activities like antioxidant, anti-tumor, antimicrobial, and antiviral activities.³ Including these activities, we can mention that chiral and achiral organoselenanes can inactivate protein tyrosine phosphatases (PTPs)⁴ and cysteine proteases⁵ (cathepsins S and V) thereby acting as enzyme inhibitors. The β -elimination reaction is the best-known reaction of selenium compounds, which involves selenoxides with a β -hydrogen atom. This reaction has been used as an efficient synthetic tool to prepare alkenes and α,β -unsaturated ketones.⁶ Selenoxides are generally prepared from the corresponding selenides using common oxidants like hydrogen peroxide and sodium metaperiodate.⁶

Besides being interesting synthetic intermediates, chiral organoselenium compounds have been satisfactorily used as catalysts or chiral ligands in organic transformations such as hydrosilylation

of enamines and ketones, enantioselective addition of diorganozinc to aldehydes and enantioselective conjugate addition of organometallic to enones.² Indeed, asymmetric synthesis using organochalcogen compounds in general is of current interest in the field of organometallic chemistry.⁷ Despite the great usefulness of chiral selenides, the asymmetric synthesis of optically active organoselenium compounds is still a challenge in selenium chemistry.⁸

Very few studies on the enzymatic reactions of selenium compounds for synthetic purposes have been published to date.⁹ Enzymatic processes, due to their wide applications under mild conditions, are environmentally friendly reactions. From the synthetic organic point of view the enzyme-catalyzed reactions present a vast opportunity to selenium chemistry regarding selectivity, including regio-, enantio-, and chemoselectivity.

In the search for novel chiral-centered selenium compounds to be used in our studies for the development of protease inhibitors,^{4,5} we encountered a lack of synthetic methodologies to obtain such compounds. We here describe a study about the application of different chemoenzymatic approaches to obtain chiral-centered selenium compounds, see Fig. 1. An oxidative approach was applied to racemic organoselenium compounds in order to perform their kinetic resolution in enzyme-mediated reactions (Fig. 1a). The second approach involved kinetic resolution of precursor 1-phenylethanols by lipases, and their transformation to the desired chiral organoselenium compounds using selenium chemistry (Fig. 1b).

* Corresponding author. Tel.: +55 11 3091 2287; fax: +55 11 3815 5579; e-mail address: leandroh@iq.usp.br (L.H. Andrade).

Fig. 1. Chemoenzymatic approaches to obtain chiral-centered selenium compounds.

2. Results and discussion

2.1. Synthesis of chiral-centered selenium compounds: kinetic resolution using a selenium oxidation approach

Initially, we synthesized phenylselenium derivatives (**1–3**) in which the selenium atom is attached to a phenyl and a 1-phenylethyl group. The protocol was based on the inversion of configuration of the phenylethanol derivatives by their reactions with phenylselenocyanide and tributylphosphine (Scheme 1).¹⁰

Scheme 1. Synthesis of selenides **1–6**: (a) PhSeCN, Bu₃P, toluene, 20 h, rt (b) DMAP, CH₂Cl₂, MsCl, 16 h, rt (c) NaBH₄, EtOH/DMF, 3 h, rt.

Next, we performed the synthesis of benzylselenides derivatives (**4–6**). Initially, mesylated phenylethanol derivatives were prepared in situ from their corresponding alcohols and mesyl chloride (MsCl). Then, benzyl selenoate was prepared from benzyl bromide (BnBr), elemental selenium, and NaBH₄, which was then transferred to the mesylated derivatives to give the benzylselenides (**4–6**) (Scheme 1).¹¹ It is noteworthy that the addition of DMF is relevant for the success of the reaction. In fact, DMF improves the yield by solubilizing the selenolate anion, which is otherwise known to exist as boron complex possessing diminished nucleophilicity.¹¹

2.1.1. Oxidative kinetic resolution of chiral selenides mediated by BVMOs. Baeyer–Villiger monooxygenases (BVMOs) are flavin-containing and NAD(P)H-dependent enzymes that catalyze the incorporation of one oxygen atom into organic substrates.¹² BVMOs usually mediate reactions with high enantio- and/or regioselectivity¹³ and they are known to be excellent alternatives for performing the oxidation of aldehydes and ketones to their corresponding esters, the oxygenation of heteroatoms (sulfur, nitrogen, phosphorus, boron, and selenium) and even epoxidation reactions.^{9c,14}

For the selenium oxidation approach using BVMOs, we first selected the phenylselenide derivative **1** as model substrate and PAMO as biocatalyst. This compound was selected to evaluate the influence of a phenyl group directly attached to the selenium atom on the oxidation reaction. We also employed a cofactor

regenerating system with phosphite dehydrogenase (PTDH) and a sacrificial substrate (sodium phosphite). In this test we observed that the oxidation reaction occurred with good enantioselectivity (84% ee, Table 1, entry 1). Next, we increased the amount of phosphite in the reaction medium leading to higher enantioselectivity (98% ee, Table 1, entry 2). By applying the same reaction conditions to compound **4** (with the benzyl group attached to the selenium atom and no substituent in the aromatic ring) lower enantioselectivity was observed (14% ee, Table 1, entries 6 and 7). As hydrogen peroxide can be produced by BVMOs, we also eval-

uated the use of catalase, an enzyme that degrades hydrogen peroxide into dioxygen and water. However, we observed several by-products even with no PAMO in the reaction medium (control reactions). These results could be due to the low purity of commercial catalase that can contain small quantities of other oxidoreductases.

In an effort to investigate other BVMOs, we performed reactions using M446G PAMO, CHMO, and HAPMO as biocatalysts. When M446G PAMO mediated the reactions, good conversions but low enantioselectivity were observed (Table 1, entries 3 and 8). When CHMO or HAPMO was employed, no reaction was observed (Table 1, entries 4, 5, 9, and 10).

By using appropriate reaction condition with PAMO, we decided to explore the oxidative kinetic resolution of several other selenides (**2**, **3**, **5**, and **6**, Table 1, entries 11–14). In all cases, the selenium oxidation was observed but with low or no enantioselectivity.

In an ideal oxidative kinetic resolution of selenides, a β -elimination reaction should be observed with one enantiomer, which would produce RSeOH and styrene derivative (RCH=CH₂), and the other enantiomer would be untouched. After assigning the absolute configuration we concluded that, when the selenium oxidation occurs, the (*R*)-selenide undergoes the oxidation faster than the (*S*)-selenide.

2.1.2. Oxidative kinetic resolution of (*RS*)-phenylselenide **1 mediated by *Aspergillus terreus*.** We have recently described that *A. terreus*

Table 1Oxidative kinetic resolution of selenium-containing aromatic compounds **1–6** mediated by BVMOs^a

Entry	Substrate	BVMO	Phosphite (mM)	Time (h)	Conv. ^b (%)	ee ^c (%)
1	1	PAMO	20	5	52	84
2	1	PAMO	50	5	49	98
3	1	M446G	50	5	45	10
4	1	HAPMO	50	24	(—) ^d	(—) ^e
5	1	CHMO	50	24	(—) ^d	(—) ^e
6	4	PAMO	20	5	53	(—) ^e
7	4	PAMO	50	5	56	14
8	4	M446G	50	5	51	10
9	4	HAPMO	50	24	(—) ^d	(—) ^e
10	4	CHMO	50	24	(—) ^d	(—) ^e
11	2	PAMO	50	8	51	9
12	3	PAMO	50	8	54	(—) ^e
13	5	PAMO	50	5	49	(—) ^e
14	6	PAMO	50	5	47	49

^a Tris buffer 50 mM pH 7.5, DMSO (1%), substrate (10 mM), phosphite (20 or 50 mM), PTDH (1 μM), NADPH (0.2 mM), and BVMO (8 μM).^b Conv.=conversion based on selenide consumption using HPLC analysis.^c Enantiomeric excess measured by HPLC.^d No reaction was observed.^e No ee was observed.

strains (URM 3571 and CCT 3320) produce oxidoreductases, which can mediate Baeyer–Villiger reactions, deracemization of several phenylethanol derivatives, and selenium oxidations.^{9d,15}

We tested these fungal strains for the oxidation of the phenylselenide derivative **1**, which was the best substrate in the previous reactions with BVMOs. The reactions were carried out using buffer, substrate, and fungal cells, which were incubated at 32 °C for 1, 3, and 5 days. All bio-oxidations were followed by a control reaction in the absence of fungal cells. However, even in 5 days, the phenylselenide **1** remained in the racemic form. This lack of reactivity can be attributed to the presence of a steric hindrance near to the selenium atom. As (*RS*)-phenylselenide **1** has two bulky moieties surrounding the selenium atom, it can be hindering the oxidation mediated by enzymes from *A. terreus*. In a previous study with fungi and organoselenium alcohols, we observed a similar result, in which selenium oxidation is very slow or does not occur at all.^{9d}

2.1.3. Oxidative kinetic resolution of (*RS*)-phenylselenide **1 mediated by *Candida antarctica* lipase B (CAL-B) in the presence of oxidants.** Lipases are also known to catalyze oxidations when in the presence of oxidizing species such as H₂O₂ or peracids, which constitutes an alternative method for bio-oxidations. They can be used in epoxidation reactions or, by lipase-mediated in situ formation of peroxy acids, even in Baeyer–Villiger reactions.¹⁶ Among the lipases studied so far, Novozym 435, a commercial preparation of lipase from *C. antarctica*, has been shown the best results in oxidative transformations becoming the most popular lipase for this purpose.¹⁶

In this context, we decided to explore the use of lipase in the presence of oxidants (H₂O₂, NaIO₄, *m*-CPBA) in order to perform enantioselective oxidation of organoselenium compounds. Therefore, the lipase-induced enantioselective oxidation reactions were carried out at 0 °C and room temperature in organic solvent. Control reactions in the absence of lipase and/or oxidant were also studied (Table 2).

Table 2Oxidative kinetic resolution of compound (*RS*)-**1** mediated by CAL-B^a

Entry	Oxidant	Solvent	Temperature (°C)	Time (h)	Conv. ^b (%)	ee ^c (<i>S</i>)- 1 (%)
1	H ₂ O ₂	Hexane	0	2	90	(—) ^e
2	H ₂ O ₂ ^f	Hexane	25	0.5	100	(—) ^e
3	NaIO ₄	Hexane	0	2	(—) ^d	(—) ^e
4	NaIO ₄	Hexane/MeOH (9:1)	25	2	5	7
5	NaIO ₄	Hexane/MeOH (1:1)	25	2	3	(—) ^e
6	NaIO ₄	Hexane/EtOAc (9:1)	25	2	(—) ^d	(—) ^e
7	NaIO ₄	Hexane/MeOH (9:1)	25	15	52	7
8	<i>m</i> -CPBA	Hexane	25	2	46	45
9	<i>m</i> -CPBA	Hexane/MeOH (9:1)	25	2	100	(—) ^e
10	<i>m</i> -CPBA	Hexane/EtOAc (9:1)	25	2	90	5
11	<i>m</i> -CPBA	Toluene	25	2	100	(—) ^e

^a Substrate (0.25 mM), solvent (1 mL), CAL-B (20 mg), oxidant (3 equiv), 0 or 25 °C, 2–15 h.^b Conv.=conversion based on selenide consumption using HPLC analysis.^c Enantiomeric excess measured by HPLC.^d No reaction was observed.^e No ee was observed.^f 2 equiv.

In most cases, no enantioselectivity (Table 2, entries 1, 2, 7, 9, 10, and 11) or no reaction was observed (Table 2, entries 3 and 6). In control reactions, we observed oxidation reaction without lipase, which can be the reason for the low enantioselectivity. However, the best system used was *m*-CPBA in *n*-hexane at room temperature (Table 2, entry 8), which resulted in enantioselective oxidation of (*R*)-**1**. In fact, these results demonstrate the potential of peracids and lipase for enantioselective selenium oxidation, without precedent until now.

2.2. Synthesis of chiral-centered selenium compounds: kinetic resolution using a transesterification approach

Another approach was evaluated to obtain both enantiomers of chiral selenides **1–6**. Kinetic resolution of phenylethanol derivatives through a lipase-catalyzed transesterification reaction was the protocol of choice. This process was performed with vinyl acetate as acyl donor and Cal-B as biocatalyst (Scheme 2).¹⁷ We obtained the corresponding (*R*)-acetate and the untouched (*S*)-alcohol in high ee, >99%.

Scheme 2. Synthesis of enantiopure chiral selenides **1–6**: (a) Cal-B, vinyl acetate, *n*-hexane, 32 °C, 160 rpm, 24 h; (b) PhSeCN, Bu₃P, THF, 16 h, rt; (c) DMAP, MsCl, CH₂Cl₂, 16 h, rt; (d) [BnSe[−]] prepared from elemental selenium, NaBH₄, benzyl bromide, EtOH/DMF, 3 h rt; (e) NaOH 1 M, MeOH, 1 h.

After column chromatography and ester hydrolysis, both enantiomerically pure phenylethanol derivatives were achieved. Then, these alcohols were transformed into the chiral selenides **1–6** using the same protocol described in the Section 2.1. As the insertion of the selenium moiety involved a Mitsunobu reaction or a nucleophilic substitution reaction with a selenolate species, we noticed that an (*S*)-alcohol will provide an (*R*)-selenide while an (*R*)-alcohol will provide an (*S*)-selenide.

3. Conclusion

Among the BVMOs tested, PAMO showed the best results for oxidation of chiral selenides. PAMO was able to oxidize phenylselenium-containing compound with no substituent in the aromatic ring with great enantioselectivity (98% ee). The mutant M446 G showed a similar substrate acceptance, but it displayed lower enantioselectivity. The BVMOs, HAPMO, and CHMO were not able to oxidize any of the tested substrates. When whole cells of *A. terreus* were used, no significant selenium oxidation was observed. By using another approach, Cal-B in the presence of *m*-CPBA as oxidant species, enantioselective conversion was observed (45% ee). By applying a different approach, lipase-catalyzed transesterification reactions provided us the enantiomerically pure alcohols, which were transformed into the desired chiral benzyl and phenylselenides.

4. Experimental

4.1. General

Recombinant phenylacetone monooxygenase (PAMO) from *Thermobifida fusca*, M446G PAMO mutant, 4-hydroxyaceto-

phenone monooxygenase (HAPMO) from *Pseudomonas fluorescens*, and cyclohexanone monooxygenase (CHMO) from *Acinetobacter* sp. were overexpressed and purified as previously described.¹⁸ Phosphite dehydrogenase was obtained as previously described.¹⁹ Both sodium phosphite and NADPH were purchased from Sigma–Aldrich. Gas chromatography (GC) analyses were performed on a Shimadzu GC-17A instrument equipped with a flame ionization detector. High performance liquid chromatography (HPLC) analyses were performed on a Shimadzu LC-

10AD or Shimadzu SPD-M10A liquid chromatograph equipped with a variable wavelength UV detector (deuterium lamp 190–600 nm). Sterile materials were used to perform the experiments involving microorganisms. A laminar flow cabinet Fisher Hamilton (Class II Biological Safety Cabinet) was used to handle microorganisms.

4.2. General procedure for synthesis of chiral organoselenium compounds (**1–3**)

The enantiomerically pure forms of 1-phenylethanols derivatives were prepared by lipase-catalyzed transesterification reactions of their racemic forms with vinyl acetate according to the methodology described in literature.¹⁷ Each enantiomer of organoselenium compounds (**1–3**) was synthesized from 1-phenylethanol derivatives by their reactions with phenylselenocyanide and tributylphosphine as described in literature.¹⁰

4.2.1. Phenyl(1-phenylethyl)selenane (1**).** Yellow oil (82%), ¹H NMR (200 MHz, CDCl₃): δ 1.73 (d, *J*=7.0 Hz, 3H), 4.43 (q, *J*=7.0 Hz), 7.20–7.60 (m, 10H). ¹³C NMR (50 MHz, CDCl₃): δ 22.1, 42.4, 127.1, 127.7, 128.3, 128.8, 129.1, 131.4, 135.4, 141.6, 143.5. LRMS (EI) *m/z* (%): 262 (M⁺, 5), 156 (8), 105 (100), 79 (10), 78 (9), 77 (14), 51 (7). FT-IR (film, cm^{−1}) ν_{max}: 3057, 2961, 2918, 1576, 1474, 1436, 1021, 762, 691, 467. [α]_D²² −70 (c 1.0, CH₂Cl₂) for (*S*)-enantiomer (ee>99%) and [α]_D²² +87 (c 1.0, CH₂Cl₂) for (*R*)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=mixture of *n*-heptane and *iso*-propanol or *n*-hexane and *iso*-propanol (99:1). Flow rate=0.5 mL/min; UV detector=254 nm; retention times: *t*_R=21.55 min (*S*) and 31.88 min (*R*) or *t*_R=16.01 min (*S*) and 31.13 min (*R*).

4.2.2. Phenyl-[1-(4-tolylethyl)]selane (2). Yellow oil (87%), ^1H NMR (200 MHz, CDCl_3): δ 1.73 (d, $J=7.0$ Hz, 3H), 2.30 (s, 3H), 4.44 (q, $J=7$ Hz, 1H), 7.04–7.63 (m, 9H). ^{13}C NMR (50 MHz, CDCl_3): δ 21.1, 22.3, 42.2, 127.0, 127.7, 129.1, 131.4, 135.2, 136.6, 140.5. LRMS (EI) m/z (%): 276 (M^+ , 4), 156 (6), 119 (100), 91 (20), 77 (12), 65 (5), 51 (4). FT-IR (film, cm^{-1}) ν_{max} : 3054, 2961, 2919, 1576, 1511, 1474, 1437, 1020, 816, 736, 689, 532, 466. $[\alpha]_{\text{D}}^{22} -151$ (c 1.0, CH_2Cl_2) for (S)-enantiomer (ee>99%) and $[\alpha]_{\text{D}}^{22} +130$ (c 1.0, CH_2Cl_2) for (R)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=*n*-heptane. Flow rate=0.5 mL/min; UV detector=220 nm; retention times: t_{R} =37.74 min (S) and 41.54 min (R).

4.2.3. 1-(4-Fluorophenyl)ethyl-phenylselane (3). Yellow oil (79%), ^1H NMR (200 MHz, CDCl_3): δ 1.72 (d, $J=7.2$ Hz, 3H), 4.43 (q, $J=7.2$ Hz, 1H), 6.80–6.96 (m, 2H), 7.14–7.28 (m, 5H), 7.38–7.43 (m, 2H). ^{13}C NMR (50 MHz, CDCl_3): δ 22.2, 41.6, 114.8, 115.2, 127.9, 128.6, 128.8, 128.8, 135.6, 161.6 (d, $J=244$ Hz). LRMS (EI) m/z (%): 280 (M^+ , 6), 262 (4), 105 (100), 91 (41), 77 (9), 65 (7), 51 (4). FT-IR (film, cm^{-1}) ν_{max} : 3070, 2965, 2864, 1602, 1508, 1223, 834, 741, 692, 533, 469. $[\alpha]_{\text{D}}^{22} -180$ (c 1.0, CH_2Cl_2) for (S)-enantiomer (ee>99%) and $[\alpha]_{\text{D}}^{22} +168$ (c 1.0, CH_2Cl_2) for (R)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=*n*-heptane. Flow rate=0.5 mL/min; UV detector=254 nm; retention times: t_{R} =27.88 min (S) and 32.61 min (R).

4.3. General procedure for synthesis of chiral organoselenium compounds (4–6)¹¹

To a 50 mL round-bottomed flask (I) were added the enantiomerically pure forms of phenylethanol derivative (1 mmol, prepared as described in Section 4.2), CH_2Cl_2 (50 mL), and DMAP (2 mmol, 0.244 g). After 15 min, MsCl (1.5 mmol, 0.12 mL) was added slowly. The reaction mixture was stirred overnight at room temperature.

In a second 50 mL round-bottomed flask (II) were added selenium (1 mmol, 0.080 g), EtOH (3 mL), DMF (2 mL), and NaBH_4 (1 mmol, 0.037 g). The mixture was stirred for 15 min and then BnBr (1 mmol, 0.119 mL) was added. After stirring 3 h at room temperature, additional amount of NaBH_4 (1.5 mmol, 0.055 g) was added. The reaction mixture was stirred over more 20 min. The content of flask (I) was added slowly to the flask (II) and the resulting mixture was stirred at room temperature for 3 h.

After that, the ethanol/DMF was removed in vacuum, and H_2O (5 mL) was added into the crude material. The resulting aqueous mixture was extracted with Et_2O (2×5 mL) and the organic extract was dried over MgSO_4 . The solvent was removed in vacuum and the mixture was purified by flash column chromatography (pentane as eluent) providing the pure product (50–75% yield).

4.3.1. Benzyl-(1-phenylethyl)selenane (4). Yellow oil (65%), ^1H NMR (200 MHz, CDCl_3): δ 1.69 (d, $J=7.0$ Hz, 3H), 3.70 (s, 2H), 4.07 (q, $J=7.0$ Hz, 1H), 7.19–7.28 (m, 10H). ^{13}C NMR (50 MHz, CDCl_3): δ 22.5, 37.7, 53.0, 126.6, 127.3, 128.3, 128.8, 139.0, 144.1. LRMS (EI) m/z (%): 276 (M^+ , 6), 262 (4), 105 (100), 91 (41), 77 (9), 65 (7), 51 (4). FT-IR (film, cm^{-1}) ν_{max} : 3026, 2920, 1493, 1452, 1177, 760, 695, 608, 478. $[\alpha]_{\text{D}}^{22} +30$ (c 1.0, CH_2Cl_2) for (S)-enantiomer (ee>99%) and $[\alpha]_{\text{D}}^{22} -45$ (c 1.0, CH_2Cl_2) for (R)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=mixture of *n*-heptane and *iso*-propanol (99:1). Flow rate=0.8 mL/min; UV detector=254 nm; retention times: t_{R} =22.75 min (S) and 26.88 min (R).

4.3.2. Benzyl-[1-(4-tolylethyl)]selenane (5). Yellow oil (50%), ^1H NMR (200 MHz, CDCl_3): δ 1.69 (d, $J=7.0$ Hz, 3H), 2.31 (s, 3H), 3.80 (s, 2H), 3.99 (q, $J=7.0$ Hz, 1H), 7.12–7.25 (m, 9H). ^{13}C NMR (50 MHz, CDCl_3): δ 21.1, 32.5, 41.0, 52.9, 127.1, 128.3, 128.9, 128.9, 137.0, 139.1, 140.0, 144.8. LRMS (EI) m/z (%): 290 (M^+ , 3), 207 (4), 182 (3), 120 (12), 119 (100), 118 (13), 117 (14), 91 (55), 77 (8), 65 (10), 51 (6). FT-IR (film, cm^{-1}) ν_{max} : 3024, 2917, 1655, 1510, 1440, 1029, 816, 757, 695, 591, 492. $[\alpha]_{\text{D}}^{22} +63$ (c 1.0, CH_2Cl_2) for (S)-enantiomer (ee>99%) and $[\alpha]_{\text{D}}^{22} -76$ (c 1.0, CH_2Cl_2) for (R)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=*n*-heptane. Flow rate=0.5 mL/min; UV detector=220 nm; retention times: t_{R} =50.65 min (S) and 54.90 min (R).

4.3.3. Benzyl-[1-(4-fluorophenyl)ethyl]selenane (6). Yellow oil (43%), ^1H NMR (200 MHz, CDCl_3): δ 1.64 (d, $J=7.2$ Hz, 3H), 3.69 (s, 2H), 3.80 (q, $J=7.2$ Hz, 1H), 6.9–7.2 (m, 9H). ^{13}C NMR (50 MHz, CDCl_3): δ 22.9, 37.6, 52.87, 114.9, 115.3, 115.3, 128.4, 128.4, 128.5, 128.7, 161.4 (d, $J=243$ Hz). LRMS (EI) m/z (%): 294 (M^+ , 4), 124 (7), 123 (100), 122 (7), 103 (20), 91 (22), 77 (5), 65 (6), 51 (3). FT-IR (film, cm^{-1}) ν_{max} : 2965, 2919, 1655, 1603, 1508, 1222, 1028, 834. $[\alpha]_{\text{D}}^{22} +84$ (c 1.0, CH_2Cl_2) for (S)-enantiomer (ee>99%) and $[\alpha]_{\text{D}}^{22} -100$ (c=1.0, CH_2Cl_2) for (R)-enantiomer (ee>99%).

The enantiomeric excess was analyzed by HPLC equipped with a Chiralcel® OJ-H column. Eluent=mixture of *n*-heptane and *iso*-propanol (99:1). Flow rate=0.5 mL/min; UV detector=220 nm; retention times: t_{R} =27.28 min (S) and 31.62 min (R).

4.4. General procedure for selenium oxidation reactions mediated by BVMOs

To a flask (2 mL, Eppendorf® tube) containing the solution of the racemic selenide compounds **1–6** (1 M in DMSO, 5 μL) were added Tris/HCl buffer at pH 7.5 (50 mM, 440 μL), phosphite solution (500 mM, 20 or 50 μL), NADPH (100 mM, 10 μL), PTDH (100 μM , 5 μL), and BVMO (100 μM , 20 or 40 μL). Reaction mixture was shaken at 200 rpm and 30 °C (PAMO and M446G PAMO mutant) or 150 rpm and 25 °C (HAPMO and CHMO) for the appropriate time (Table 1). The reaction mixture was extracted with EtOAc (3×0.5 mL) and the organic extract was dried over Na_2SO_4 and analyzed by HPLC. Control experiments in absence of enzyme were performed for all substrates, and no selenium oxidation was observed.

4.5. General procedure for selenium oxidation mediated by *A. terreus* URM 3571 and CCT 3320

Erlenmeyer flasks (250 mL) containing 100 mL of culture medium (malt extract, 20 g/L) were inoculated with *Aspergillus* spores. Growth was carried out in an orbital shaker (160 rpm) at 32 °C for 5 days. The fungal cells were harvested by filtration.

The biotransformation was performed by re-suspending the fungal cells (1 g) with Tris/HCl (50 mM, pH 7.5, 50 mL) in an Erlenmeyer flask (125 mL). To this cell suspension, selenide **1** (0.1 mmol) was added and incubated in an orbital shaker (160 rpm) at 32 °C for 1–5 days. Then reaction mixture was filtered and the aqueous layer was extracted with ethyl acetate (2×20 mL). The organic extract was dried over Na_2SO_4 and analyzed by chiral HPLC. Control experiments in absence of fungi were performed.

4.6. General procedure for selenium oxidation reactions mediated by CAL-B

To a flask (2 mL, Eppendorf® tube) containing the selenide **1** (0.25 mmol, 65 mg) were added the organic solvent (1 mL) and CAL-B (20 mg). After 5 min, the oxidant (2 or 3 equiv, 0.5 or

0.75 mmol) was added. Reaction mixture was shaken at room temperature or 0 °C for the appropriate time (Table 2). The enzyme was filtered and the solution was washed with distilled water and the aqueous layer was extracted with *n*-hexane (2×1 mL). The organic extract was dried over Na₂SO₄ and analyzed by HPLC. Control experiments in absence of enzyme and/or oxidant were performed.

Supplementary data

Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/10.1016/j.tet.2012.09.087>.

References and notes

1. Uemura, S. *Phosphorus, Sulfur Silicon Relat. Elem.* **2001**, 171, 13–30.
2. Godoi, M.; Paixão, M. W.; Braga, A. L. *Dalton Trans.* **2011**, 40, 11347–11355 and references therein.
3. (a) Mugesh, G.; Singh, H. *Chem. Soc. Rev.* **2000**, 29, 347–357; (b) Nogueira, C. W.; Zeni, G.; Rocha, J. B. T. *Chem. Rev.* **2004**, 104, 6255–6286.
4. (a) Abdo, M.; Liu, S.; Zhou, B.; Walls, C. D.; Wu, L.; Knapp, S.; Zhang, Z.-Y. *J. Am. Chem. Soc.* **2008**, 130, 13196–13197; (b) Piovan, L.; Alves, M. F. M.; Juliano, L.; Bromme, D.; Cunha, R. L. O. R.; Andrade, L. H. *J. Braz. Chem. Soc.* **2010**, 21, 2108–2118; (c) Piovan, L.; Wu, L.; Zhang, Z.; Andrade, L. H. *Org. Biomol. Chem.* **2011**, 9, 1347–1351.
5. Piovan, L.; Alves, M. F. M.; Juliano, L.; Bromme, D.; Cunha, R. L. O. R.; Andrade, L. H. *Bioorg. Med. Chem.* **2011**, 19, 2009–2014.
6. Ogawa, A. *Selenium and Tellurium in Organic Synthesis In Main Group Metal in Organic Synthesis*; Yamamoto, H., Oshima, K., Eds.; Wiley-VCH: Weinheim, 2005.
7. Mugesh, G.; Singh, H. B. *Acc. Chem. Res.* **2002**, 35, 226–236.
8. (a) Zhu, C.; Huang, Y. *Curr. Org. Chem.* **2006**, 10, 1905–1920 and references therein; (b) Ruano, J. L. G.; Torrente, E.; Alonso, I.; Rodríguez, M.; Martín-Castro, A. M.; Degl'Innocenti, A.; Frateschi, L.; Capperucci, A. *J. Org. Chem.* **2012**, 77, 1974–1982.
9. (a) Holland, H. I.; Carter, I. M. *Bioorg. Chem.* **1983**, 12, 1–7; (b) Latham, J. A.; Branchaud, B. P.; Chen, Y. C. J.; Walsh, C. J. *Chem. Soc., Chem. Commun.* **1986**, 528–530; (c) Branchaud, B. P.; Walsh, C. T. *J. Am. Chem. Soc.* **1985**, 107, 2153–2161; (d) Da Costa, C. E.; Comasseto, J. V.; Crusius, I. H. S.; Andrade, L. H.; Porto, A. L. M. *J. Mol. Catal. B: Enzym.* **2007**, 45, 135–139; (e) Andrade, L. H.; Pedrozo, E. C.; Leite, H. G.; Brondani, P. B. *J. Mol. Catal. B: Enzym.* **2011**, 73, 63–66; (f) Comasseto, J. V.; Gariani, R. A. *Tetrahedron* **2009**, 65, 8447–8459.
10. Clive, D. I. J.; Chittattu, G. J.; Farina, V.; Kiel, W. A.; Menchen, S. M.; Russel, C. G.; Singh, A.; Wong, C. K.; Curtis, N. J. *J. Am. Chem. Soc.* **1980**, 102, 4438–4447.
11. Wirth, T.; Cox, M. *Phosphorus, Sulfur Silicon Relat. Elem.* **2007**, 180, 659–666.
12. (a) Pazmiño, D. E. T.; Dudek, H.; Fraaije, M. W. *Curr. Opin. Chem. Biol.* **2010**, 14, 138–144; (b) Nolan, L. C.; O'Connor, K. E. *Biotechnol. Lett.* **2008**, 30, 1879–1891; (c) Van Berkel, W. J. H.; Kamerbeek, N. M.; Fraaije, M. W. *J. Biotechnol.* **2006**, 124, 670–689.
13. (a) De Gonzalo, G.; Mihovilovic, M. D.; Fraaije, M. W. *ChemBioChem* **2010**, 11, 2208–2231; (b) Kayser, M. M. *Tetrahedron* **2009**, 65, 947–974; (c) Mihovilovic, M. D. *Curr. Org. Chem.* **2006**, 10, 1265–1287; (d) Kamerbeek, N. M.; Janssen, D. B.; van Berkel, W. J. H.; Fraaije, M. W. *Adv. Synth. Catal.* **2003**, 345, 667–678.
14. (a) Colonna, S.; Gaggero, N.; Carrea, G.; Ottolina, G.; Pasta, P.; Zambianchi, F. *Tetrahedron Lett.* **2002**, 43, 1797–1799.
15. (a) Keppler, A. F.; Porto, A. L. M.; Crusius, I. H. S.; Comasseto, J. V.; Andrade, L. H. *Enzyme Microb. Technol.* **2005**, 36, 967–975; (b) Assis, L. F.; Kagohara, E.; Omori, A. T.; Comasseto, J. V.; Andrade, L. H.; Porto, A. L. M. *Food Technol. Biotechnol.* **2007**, 45, 415–419.
16. (a) Xu, Y.; Khaw, N. R. B. J.; Li, Z. *Green Chem.* **2009**, 11, 2047–2051; (b) Orellana-Coca, C.; Camacho, S.; Adlercreutz, D.; Mattiasson, B.; Hatti-Kaul, R. *Eur. J. Lipid Sci. Technol.* **2005**, 107, 864–870; (c) Moreira, A. M.; Nascimento, M. G. *Catal. Commun.* **2007**, 8, 2043–2047.
17. (a) Cheng, Y.; Xu, G.; Wu, J.; Zhang, C.; Yang, L. *Tetrahedron Lett.* **2010**, 51, 2366–2369 and references therein; (b) Andrade, L. H.; Omori, A. T.; Porto, A. L. M.; Comasseto, J. V. *J. Mol. Catal. B: Enzym.* **2004**, 29, 47–54.
18. (a) Fraaije, M. W.; Wu, J.; Heuts, D. P. H. M.; van Hellemond, E. W.; Spelberg, J. H. L.; Janssen, D. B. *Appl. Microbiol. Biotechnol.* **2005**, 66, 393–400; (b) Kamerbeek, N. M.; Moonen, M. J. H.; van der Ven, J. G. M.; van Berkel, W. J. H.; Fraaije, M. W.; Janssen, D. B. *Eur. J. Biochem.* **2001**, 268, 2547–2557; (c) Donoghue, N. A.; Norris, D. B.; Trudgill, P. W. *Eur. J. Biochem.* **1976**, 63, 175–192.
19. Dudek, H. M.; Gonzalo, G.; Pazmiño, D. E. T.; Stepniak, P.; Wyrwicz, L. S.; Rychlewski, L.; Fraaije, M. W. *Appl. Environ. Microbiol.* **2011**, 77, 5730–5738.